Literature DB >> 29394516

CA1 pyramidal neuron gene expression mosaics in the Ts65Dn murine model of Down syndrome and Alzheimer's disease following maternal choline supplementation.

Melissa J Alldred1,2, Helen M Chao1,2, Sang Han Lee3,4, Judah Beilin1, Brian E Powers5, Eva Petkova6,4, Barbara J Strupp7,5, Stephen D Ginsberg1,2,8,9.   

Abstract

Although there are changes in gene expression and alterations in neuronal density and afferent inputs in the forebrain of trisomic mouse models of Down syndrome (DS) and Alzheimer's disease (AD), there is a lack of systematic assessments of gene expression and encoded proteins within individual vulnerable cell populations, precluding translational investigations at the molecular and cellular level. Further, no effective treatment exists to combat intellectual disability and basal forebrain cholinergic neurodegeneration seen in DS. To further our understanding of gene expression changes before and following cholinergic degeneration in a well-established mouse model of DS/AD, the Ts65Dn mouse, we assessed RNA expression levels from CA1 pyramidal neurons at two adult ages (∼6 months of age and ∼11 months of age) in both Ts65Dn and their normal disomic (2N) littermates. We further examined a therapeutic intervention, maternal choline supplementation (MCS), which has been previously shown to lessen dysfunction in spatial cognition and attention, and have protective effects on the survival of basal forebrain cholinergic neurons in the Ts65Dn mouse model. Results indicate that MCS normalized expression of several genes in key gene ontology categories, including synaptic plasticity, calcium signaling, and AD-associated neurodegeneration related to amyloid-beta peptide (Aβ) clearance. Specifically, normalized expression levels were found for endothelin converting enzyme-2 (Ece2), insulin degrading enzyme (Ide), Dyrk1a, and calcium/calmodulin-dependent protein kinase II (Camk2a), among other relevant genes. Single population expression profiling of vulnerable CA1 pyramidal neurons indicates that MCS is a viable therapeutic for long-term reprogramming of key transcripts involved in neuronal signaling that are dysregulated in the trisomic mouse brain which have translational potential for DS and AD.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  choline supplementation; hippocampus; laser capture microdissection; microarray; trisomic

Mesh:

Substances:

Year:  2018        PMID: 29394516      PMCID: PMC5874173          DOI: 10.1002/hipo.22832

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  143 in total

Review 1.  Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome.

Authors:  Mohammed Rachidi; Carmela Lopes
Journal:  Am J Intellect Dev Disabil       Date:  2010-03

2.  ADAM10 and BACE1 are localized to synaptic vesicles.

Authors:  Jolanta L Lundgren; Saheeb Ahmed; Sophia Schedin-Weiss; Gunnar K Gouras; Bengt Winblad; Lars O Tjernberg; Susanne Frykman
Journal:  J Neurochem       Date:  2015-09-17       Impact factor: 5.372

Review 3.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

4.  Transcriptional profiling of small samples in the central nervous system.

Authors:  Stephen D Ginsberg
Journal:  Methods Mol Biol       Date:  2008

5.  Reduction of synaptojanin 1 accelerates Aβ clearance and attenuates cognitive deterioration in an Alzheimer mouse model.

Authors:  Li Zhu; Minghao Zhong; Jiaying Zhao; Hannah Rhee; Ina Caesar; Elysse M Knight; Laura Volpicelli-Daley; Victor Bustos; William Netzer; Lijuan Liu; Louise Lucast; Michelle E Ehrlich; Nikolaos K Robakis; Samuel E Gandy; Dongming Cai
Journal:  J Biol Chem       Date:  2013-09-19       Impact factor: 5.157

Review 6.  Insulin-degrading enzyme: a link between Alzheimer's and type 2 diabetes mellitus.

Authors:  Rizwanul Haque; Aamir Nazir
Journal:  CNS Neurol Disord Drug Targets       Date:  2014-03       Impact factor: 4.388

7.  Brain acetylcholine and choline concentrations and dynamics in a murine model of the Fragile X syndrome: age, sex and region-specific changes.

Authors:  O U Scremin; M Roch; K M Norman; S Djazayeri; Y-Y Liu
Journal:  Neuroscience       Date:  2015-06-24       Impact factor: 3.590

8.  Perinatal Phosphatidylcholine Supplementation and Early Childhood Behavior Problems: Evidence for CHRNA7 Moderation.

Authors:  Randal G Ross; Sharon K Hunter; M Camille Hoffman; Lizbeth McCarthy; Betsey M Chambers; Amanda J Law; Sherry Leonard; Gary O Zerbe; Robert Freedman
Journal:  Am J Psychiatry       Date:  2015-12-07       Impact factor: 18.112

9.  The topography of plaques and tangles in Down's syndrome patients of different ages.

Authors:  D M Mann; P O Yates; B Marcyniuk; C R Ravindra
Journal:  Neuropathol Appl Neurobiol       Date:  1986 Sep-Oct       Impact factor: 8.090

10.  BACE1 is necessary for experience-dependent homeostatic synaptic plasticity in visual cortex.

Authors:  Emily Petrus; Hey-Kyoung Lee
Journal:  Neural Plast       Date:  2014-05-14       Impact factor: 3.599

View more
  13 in total

1.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

2.  Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology.

Authors:  Stephen D Ginsberg; Michael H Malek-Ahmadi; Melissa J Alldred; Yinghua Chen; Kewei Chen; Moses V Chao; Scott E Counts; Elliott J Mufson
Journal:  Neurobiol Dis       Date:  2019-07-23       Impact factor: 5.996

3.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

4.  Long-term effects of maternal choline supplementation on CA1 pyramidal neuron gene expression in the Ts65Dn mouse model of Down syndrome and Alzheimer's disease.

Authors:  Melissa J Alldred; Helen M Chao; Sang Han Lee; Judah Beilin; Brian E Powers; Eva Petkova; Barbara J Strupp; Stephen D Ginsberg
Journal:  FASEB J       Date:  2019-06-10       Impact factor: 5.191

5.  Hyper-Rigid Phasic Organization of Hippocampal Activity But Normal Spatial Properties of CA1 Place Cells in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Robert G K Munn; Aimée Freeburn; David P Finn; H Craig Heller
Journal:  J Neurosci       Date:  2022-01-03       Impact factor: 6.709

Review 6.  Neuroprotective Effects of Choline and Other Methyl Donors.

Authors:  Rola A Bekdash
Journal:  Nutrients       Date:  2019-12-06       Impact factor: 5.717

7.  Mitovesicles are a novel population of extracellular vesicles of mitochondrial origin altered in Down syndrome.

Authors:  Pasquale D'Acunzo; Rocío Pérez-González; Yohan Kim; Tal Hargash; Chelsea Miller; Melissa J Alldred; Hediye Erdjument-Bromage; Sai C Penikalapati; Monika Pawlik; Mitsuo Saito; Mariko Saito; Stephen D Ginsberg; Thomas A Neubert; Chris N Goulbourne; Efrat Levy
Journal:  Sci Adv       Date:  2021-02-12       Impact factor: 14.136

Review 8.  Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease.

Authors:  Jose L Martinez; Matthew D Zammit; Nicole R West; Bradley T Christian; Anita Bhattacharyya
Journal:  Front Aging Neurosci       Date:  2021-07-12       Impact factor: 5.702

9.  Profiling Basal Forebrain Cholinergic Neurons Reveals a Molecular Basis for Vulnerability Within the Ts65Dn Model of Down Syndrome and Alzheimer's Disease.

Authors:  Melissa J Alldred; Sai C Penikalapati; Sang Han Lee; Adriana Heguy; Panos Roussos; Stephen D Ginsberg
Journal:  Mol Neurobiol       Date:  2021-07-14       Impact factor: 5.682

Review 10.  Choline, Neurological Development and Brain Function: A Systematic Review Focusing on the First 1000 Days.

Authors:  Emma Derbyshire; Rima Obeid
Journal:  Nutrients       Date:  2020-06-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.